https://wikimd.org/index.php?action=history&feed=atom&title=FidaxomicinFidaxomicin - Revision history2026-04-27T12:35:53ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Fidaxomicin&diff=5805899&oldid=prevPrab: CSV import2024-05-22T15:34:52Z<p>CSV import</p>
<p><b>New page</b></p><div>[[File:Fidaxomicin.svg|thumb|Fidaxomicin.svg]] '''Fidaxomicin''' is a [[macrolide]] antibiotic used primarily for the treatment of [[Clostridioides difficile infection]] (CDI), a condition that can cause severe [[diarrhea]] and [[colitis]]. It is known for its narrow spectrum of activity, which targets [[Clostridioides difficile]] with minimal impact on the normal [[gut flora]].<br />
<br />
==Mechanism of Action==<br />
Fidaxomicin works by inhibiting the [[bacterial]] enzyme [[RNA polymerase]], which is essential for [[transcription (biology)|transcription]] and subsequent [[protein synthesis]]. This inhibition leads to the death of the [[bacteria]], effectively treating the infection.<br />
<br />
==Pharmacokinetics==<br />
Fidaxomicin is minimally absorbed from the [[gastrointestinal tract]], which allows it to act locally in the [[intestines]]. This property is beneficial as it reduces the risk of systemic side effects and maintains a high concentration of the drug at the site of infection.<br />
<br />
==Clinical Use==<br />
Fidaxomicin is specifically indicated for the treatment of [[Clostridioides difficile infection]] in adults. It is often reserved for cases where other treatments, such as [[metronidazole]] or [[vancomycin]], have failed or are not suitable.<br />
<br />
==Side Effects==<br />
Common side effects of fidaxomicin include [[nausea]], [[vomiting]], and [[abdominal pain]]. Serious side effects are rare but can include [[hypersensitivity reactions]].<br />
<br />
==Comparison with Other Treatments==<br />
Compared to other antibiotics like [[metronidazole]] and [[vancomycin]], fidaxomicin has a lower recurrence rate of [[Clostridioides difficile infection]]. This makes it a valuable option in the management of recurrent CDI.<br />
<br />
==History==<br />
Fidaxomicin was approved by the [[Food and Drug Administration]] (FDA) in 2011 for the treatment of [[Clostridioides difficile infection]]. It was developed by [[Optimer Pharmaceuticals]] and is marketed under the brand name Dificid.<br />
<br />
==Research and Development==<br />
Ongoing research is exploring the use of fidaxomicin in pediatric populations and its potential effectiveness against other [[bacterial infections]].<br />
<br />
==See Also==<br />
* [[Clostridioides difficile]]<br />
* [[Macrolide antibiotics]]<br />
* [[Antibiotic resistance]]<br />
* [[Gastrointestinal tract]]<br />
<br />
==References==<br />
{{Reflist}}<br />
<br />
==External Links==<br />
{{No external links}}<br />
<br />
[[Category:Antibiotics]]<br />
[[Category:Macrolides]]<br />
[[Category:Infectious diseases]]<br />
[[Category:2011 introductions]]<br />
[[Category:Medicine]]<br />
<br />
{{medicine-stub}}</div>Prab